

Dear

Dr Henning Gädeke, Chair of the Global Health EDCTP3
Joint Undertaking Governing Board

c/o Dr Michael Makanga, Global Health EDCTP3 Joint
Undertaking Executive Director

Global Health EDCTP3 Joint Undertaking

56 – 60 Avenue de la Toison d'Or

1060 Brussels

Belgium

Cervarese Santa Croce, 10.09.202

Subject: Letter of endorsement

Dear Sir,

On behalf of EOS srl, a company organized under the laws of the Italian Republic with its principal place of business Via Fossona 7/a, 35030 Cervarese Santa Croce (PD) Italy, VAT #04246700282, and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

EOS srl, is an Italian company operating in the development and commercialization of diagnostic devices and analytical platform, including liquid chromatography – tandem mass spectrometry platforms and with a strong commitment to support Clinical Research and Innovation in In-Vitro Diagnostics, improving healthcare at international level, in accordance with the objectives of Global Health EDCTP3 JU.

EOS srl has a strong collaborative link with the University of Turin and, considering the objectives of the company, is willing to contribute with IKOP to University of Turin, by providing, waiving its Depreciation costs, a regenerated, highly sensitive and specific, ultra-high performance liquid chromatography – tandem mass spectrometry system (Shimadzu Nexera-X2 UHPLC coupled with a LCMS-8060 tandem-mass spectrometer) for 4 years, at a dedicated facility in Corso Svizzera 185, Turin.

This instrumentation will be used to support the HORIZON-JU-CSA “RAPID” proposal, submitted to the HORIZON-JU-GH-EDCTP3-2025-03-two-stage call for pandemic preparedness, for the achievement of the objectives of the WP10 and WP11, consisting in:

- *Development of Bioanalytical Methods for the quantification of antinfective drugs to be trialled.*
- *Training of personnel from African Institutions to build capacity for PK analysis*
- *Cross-validating bioanalytical methods for PK analysis developed at African Institutions.*

The instrumentation will be accessible under the supervision of the WP leader Prof. Amedeo De Nicolò, Associate Professor of Pharmacology at the University of Turin, Department of Medical Sciences.


We estimate the total value of this contribution to be EUR 100.000, considering a depreciation rate of 25.000 EUR/year.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programs and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorized by Global Health EDCTP3 JU. Internal dissemination of information within our organization will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.

5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

EOS srl

Fabio Sgarabottolo

